Media releases & Ad hoc announcements Keyword Search Clear 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 20 September 2021 New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer more Published on: 17 September 2021 Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer more Published on: 15 September 2021 Roche opens access to pathology imaging tools to improve patient care more Published on: 9 September 2021 Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases more Published on: 7 September 2021 Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers more Published on: 27 August 2021 Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer more Published on: 18 August 2021 Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy more Published on: 9 August 2021 [Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care more Published on: 3 August 2021 US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer more Published on: 29 July 2021 FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) more Published on: 29 July 2021 Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) more Published on: 22 July 2021 [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results more Published on: 21 July 2021 FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes more Published on: 20 July 2021 Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 more Published on: 19 July 2021 New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A more Published on: 9 July 2021 WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis more Published on: 2 July 2021 Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care more Published on: 28 June 2021 Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) more Published on: 25 June 2021 Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children more Published on: 24 June 2021 FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) more Published on: 15 June 2021 Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio more Published on: 11 June 2021 Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia more Published on: 11 June 2021 New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA) more Published on: 8 June 2021 Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home more Published on: 4 June 2021 Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma more Published on: 25 May 2021 European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy more Published on: 20 May 2021 Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning more Published on: 11 May 2021 Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer more Published on: 5 May 2021 Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer more Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer more Published on: 28 April 2021 Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people more Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer more Published on: 23 April 2021 CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD) more Published on: 23 April 2021 Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy more Published on: 22 April 2021 Roche purchases shares in tender offer for GenMark Diagnostics, Inc. more Published on: 21 April 2021 Roche reports solid results in the first quarter of 2021 more Published on: 16 April 2021 New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis more Published on: 15 April 2021 Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) more Published on: 13 April 2021 FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications more Published on: 12 April 2021 Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% more Published on: 8 April 2021 New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio more Published on: 7 April 2021 Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types more Published on: 31 March 2021 Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging more Published on: 30 March 2021 Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy more Published on: 26 March 2021 Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer more Published on: 25 March 2021 Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash more Published on: 23 March 2021 Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency more Published on: 23 March 2021 New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 more Published on: 22 March 2021 Roche provides update on tominersen programme in manifest Huntington’s disease more Published on: 22 March 2021 Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning more Published on: 17 March 2021 Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs more Published on: 16 March 2021 Roche Annual General Meeting 2021 more Published on: 16 March 2021 Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations more Published on: 16 March 2021 New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) more Published on: 15 March 2021 Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample more Published on: 11 March 2021 Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems more Published on: 11 March 2021 Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia more Published on: 8 March 2021 Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer more Published on: 5 March 2021 Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition more Published on: 26 February 2021 Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany more Published on: 26 February 2021 EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 more Published on: 26 February 2021 Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older more Published on: 25 February 2021 Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine more Published on: 12 February 2021 New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients more Published on: 8 February 2021 FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients more Published on: 4 February 2021 Roche reports solid results in 2020 more Published on: 1 February 2021 Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection more Published on: 25 January 2021 Roche renews partnership with Sysmex to deliver haematology testing solutions more Published on: 25 January 2021 Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration more Published on: 18 January 2021 Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy more Published on: 12 January 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab more Published on: 12 January 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer more Published on: 11 January 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer more Published on: 11 January 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years more Published on: 5 January 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer more
Published on: 20 September 2021 New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer more
Published on: 17 September 2021 Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer more
Published on: 15 September 2021 Roche opens access to pathology imaging tools to improve patient care more
Published on: 9 September 2021 Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases more
Published on: 7 September 2021 Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers more
Published on: 27 August 2021 Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer more
Published on: 18 August 2021 Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy more
Published on: 9 August 2021 [Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care more
Published on: 3 August 2021 US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer more
Published on: 29 July 2021 FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) more
Published on: 29 July 2021 Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) more
Published on: 22 July 2021 [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results more
Published on: 21 July 2021 FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes more
Published on: 20 July 2021 Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 more
Published on: 19 July 2021 New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A more
Published on: 9 July 2021 WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis more
Published on: 2 July 2021 Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care more
Published on: 28 June 2021 Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) more
Published on: 25 June 2021 Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children more
Published on: 24 June 2021 FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) more
Published on: 15 June 2021 Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio more
Published on: 11 June 2021 Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia more
Published on: 11 June 2021 New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA) more
Published on: 8 June 2021 Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home more
Published on: 4 June 2021 Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma more
Published on: 25 May 2021 European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy more
Published on: 20 May 2021 Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning more
Published on: 11 May 2021 Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer more
Published on: 5 May 2021 Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer more
Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer more
Published on: 28 April 2021 Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people more
Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer more
Published on: 23 April 2021 CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD) more
Published on: 23 April 2021 Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy more
Published on: 22 April 2021 Roche purchases shares in tender offer for GenMark Diagnostics, Inc. more
Published on: 16 April 2021 New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis more
Published on: 15 April 2021 Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) more
Published on: 13 April 2021 FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications more
Published on: 12 April 2021 Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% more
Published on: 8 April 2021 New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio more
Published on: 7 April 2021 Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types more
Published on: 31 March 2021 Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging more
Published on: 30 March 2021 Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy more
Published on: 26 March 2021 Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer more
Published on: 25 March 2021 Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash more
Published on: 23 March 2021 Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency more
Published on: 23 March 2021 New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 more
Published on: 22 March 2021 Roche provides update on tominersen programme in manifest Huntington’s disease more
Published on: 22 March 2021 Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning more
Published on: 17 March 2021 Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs more
Published on: 16 March 2021 Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations more
Published on: 16 March 2021 New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) more
Published on: 15 March 2021 Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample more
Published on: 11 March 2021 Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems more
Published on: 11 March 2021 Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia more
Published on: 8 March 2021 Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer more
Published on: 5 March 2021 Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition more
Published on: 26 February 2021 Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany more
Published on: 26 February 2021 EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 more
Published on: 26 February 2021 Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older more
Published on: 25 February 2021 Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine more
Published on: 12 February 2021 New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients more
Published on: 8 February 2021 FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients more
Published on: 1 February 2021 Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection more
Published on: 25 January 2021 Roche renews partnership with Sysmex to deliver haematology testing solutions more
Published on: 25 January 2021 Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration more
Published on: 18 January 2021 Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy more
Published on: 12 January 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab more
Published on: 12 January 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer more
Published on: 11 January 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer more
Published on: 11 January 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years more
Published on: 5 January 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer more